HBIO Harvard Bioscience Inc.

Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023

Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023

HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas. Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer.

The Company’s presentation will begin at 9:40 AM ET / 8:40 AM CT on November 16th. A replay of the presentation will be available on the Investor Relations section Harvard Bioscience  shortly after the presentation has concluded.

Harvard Bioscience will also host one-on-one meetings with investors on Thursday, November 16. To register for the conference or to schedule a one-on-one meeting, please visit .

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at

Investor Inquiries:

Harvard Bioscience, Inc.

Investor Relations

(508) 893-3120



EN
09/11/2023

Underlying

HBIOHarvard Bioscience Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harvard Bioscience Inc.

 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Expands Distribution Agreement with Fisher Scientif...

Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States - Strategic expansion with trusted partner enhances customer reach HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world’s largest and most trusted scientific suppliers. Under this new agreement, Fisher Scientific ...

September 16, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board ...

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors Veteran life sciences industry financing leader appointed as new Board member HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board’s Nominating and Governance Committee. “We are pleased to announce Steve as the newest member of our Board of Directors at such an important time fo...

September 9, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Second Quarter 2025 Financial Results

Harvard Bioscience Announces Second Quarter 2025 Financial Results Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by OperationsThird Quarter 2025 Guidance Reflects Improved Operations and Strong Financial DisciplineNew Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2025. “We made solid progress in the second quarter exceeding our rev...

August 11, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference C...

Harvard Bioscience Schedules Second Quarter 2025 Earnings Conference Call for August 11, 2025 at 8:00 AM ET HOLLISTON, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2025, before the market opens on August 11, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join...

August 4, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two ...

Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance HOLLISTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced a CEO succession plan under which John Duke will assume the role of President & CEO followi...

July 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch